Regeneron Pharmaceuticals Stock News

Equity markets have been volatile throughout the year. We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer.

TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Regeneron Pharmaceuticals, Inc. faces declining Eylea sales due to competition from Roche's Vabysmo and biosimilars like Amgen's Pavblu, but Dupixent's strong growth and new indications provide a robust near-term revenue driver. Libtayo and the oncology pipeline offer potential, but face tough competition and are unlikely to become blockbuster catalysts in the short term. The company's move int...

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the elderly and is characterized by itchiness, blisters and lesions.

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP